Search
Bright Minds Biosciences Inc
DRUGAdd to Watchlist
53.510USD
-4.410-7.61%
Close 09-24 16:00（ET）
524.93MMarket Cap
LossP/E TTM
Bright Minds Biosciences Inc (DRUG) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Bright Minds Biosciences Inc in the past month.
Buy
3 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
148.557USD+156.49%
DRUG Analyst Recommendation Trends
In the current month, DRUG has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DRUG average Analyst price target in the last month is 148.557.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
2
2
2
2
2
4
4
4
4
4
4
4
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
6
6
6
6
7
Financial Forecasting
Based on analysts' estimates, DRUG EPS is projected to reach -1.045 in FY2026Q4, following reported EPS of -0.172 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.87
-0.85
-1.25
-1.05
-1.16
Actual
-0.71
-0.78
-0.17
--
--
Surprise
+18.25%
+7.38%
+86.25%
--
--
FAQs
What is Bright Minds Biosciences Inc's price target?
Analysts forecast that Bright Minds Biosciences Inc's price target is USD 80.00, with the highest forecast at USD 93.00 and the lowest forecast at USD 72.00.
How have Bright Minds Biosciences IncDRUG's recent earnings per share performed?
The market expectation was USD -0.17, while Bright Minds Biosciences IncDRUG's earnings per share (EPS) for the previous quarter was USD -0.78. EPS for the next quarter is expected at USD -1.05.
What is the analyst rating for Bright Minds Biosciences Inc?
Based on the ratings of Bright Minds Biosciences Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.